Savara Inc (SVRA) Stock Price, Quote & News

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 512 614 1848

Website: www.savarapharma.com

Address:

1717 Langhorne Newtown Road, Suite 300, Langhorne, United States

TheThroatSlasher Jun. 12 at 1:07 PM

$SVRA this is a turd A slippery greasy stinky turd It was flushed 8-9 months ago but won’t go down, it just keeps floating

0 · Reply

arben1 Jun. 11 at 9:10 PM

$SVRA this company it’s all about survival. Lost money years go.just stay in my watch list to see at least patient can benefit

0 · Reply

art62 Jun. 4 at 10:18 PM

$SVRA "(1) SVRA expects to receive the FDA Type A meeting minutes by Aug 25, 2025, or within 90 days of the May 27 refuse-to-file (RTF) letter. Mgmt will submit a Type A meeting request within 30 days of the RTF, followed by another 30 days for the FDA to grant a meeting and an add'l 30 days for the formal meeting minutes..... we can expect SVRA to update the Street by Aug 25, 2025. SVRA has been conversing with the members of DPACC pulmonology/allergy division at CDER (vs CBER). Ultimately,... once BLA refiles in Q4:25. Our precedent analysis suggests this timeline seems doable. (2) The RTF seems related to mgmt's oversight more than anything. The FDA's requests are unrelated to any clinical trial, safety, or inconsistent CMC issues. Rather, the RTF is due to 'in-process' analytical testing being incomplete. Instead, the FDA wanted the data now. In any case, SVRA should complete in-process testing by Q3:25." tsai

0 · Reply

GoldenTradesCapital Jun. 2 at 4:30 PM

Five penny stocks with great growth potential 📈 • $SPRO – Spero Therapeutics, Inc. • $SVRA – Savara Inc. • $IBRX – ImmunityBio, Inc. • $UUUU – Energy Fuels Inc. • $SPCE – Virgin Galactic Holdings, Inc.

1 · Reply

JambaPotato May. 30 at 2:05 PM

$SVRA Amazing lack of management focus given the apparent efficacy of the drug and most of them with underwater substantial stock ownership now; hopefully only temporary. What possibly could be the holdup to file quickly, get this moving again within days, not months? Especially with Breakthrough Drug designation and FDA consults available.

1 · Reply

art62 May. 30 at 3:41 AM

$SVRA let's face it any one of us could a more competent job than these useless scum , this company needs just maybe two or three people at most that are spending more time on FDA approval than awarding options.

0 · Reply

Spacemonkey1 May. 29 at 9:30 PM

$SVRA my suggestion is, email Savara at [email protected], here are my questions What is the strategy to shore up investor confidence after the latest debacle? For those of us who’ve been here since the MAST merger, this latest setback is crushing. As noted by analysts, the lack of investor communication is problematic. Please address to this shareholder what went wrong? What is the plan to fix it? Why are we waiting so long to resubmit to the FDA? Why should we continue to support this management team, whose performance, frankly, does not inspire any confidence after the, latest, setback?

2 · Reply

Spacemonkey1 May. 29 at 9:16 PM

$SVRA the only question I have is whether this is a new RFK, Jackass Fda policy trying to get people to manufacture drugs in the US. If so, that’s a disaster for the entirety of medicine and patients to delay drugsto force that

0 · Reply

Spacemonkey1 May. 29 at 9:15 PM

$SVRA I don’t know if there is a more damning statement about the utter leadership failure that occurred. Time to cut bait. Bring in someone experienced to get over the finish line

0 · Reply

Spacemonkey1 May. 29 at 9:13 PM

$SVRA on HC Wainwright downgrade “The analyst expressed disappointment in the lack of a clear and straightforward path forward communicated by Savara's management, especially given the drug's designation and the ongoing discussions with the FDA. Such a designation typically indicates a more interactive and positive dialogue with the agency, which should not lead to filing refusals.”

0 · Reply

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 27, 2025, 3:40 PM EDT - 25 days ago

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

May 27, 2025, 11:42 AM EDT - 25 days ago

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

May 27, 2025, 8:05 AM EDT - 25 days ago

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

May 23, 2025, 4:05 PM EDT - 4 weeks ago

Savara Announces New Employment Inducement Grant

May 22, 2025, 9:05 AM EDT - 4 weeks ago

Savara Announces Participation in Jefferies Global Healthcare Conference

May 18, 2025, 2:30 PM EDT - 4 weeks ago

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

May 13, 2025, 4:05 PM EDT - 5 weeks ago

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

May 12, 2025, 4:05 PM EDT - 5 weeks ago

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

May 1, 2025, 4:05 PM EDT - 7 weeks ago

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Apr 21, 2025, 11:16 AM EDT - 2 months ago

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 7, 2025, 4:05 PM EDT - 2 months ago

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Mar 27, 2025, 7:05 AM EDT - 3 months ago

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 26, 2025, 4:45 PM EDT - 3 months ago

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

HTGC

Mar 26, 2025, 4:05 PM EDT - 3 months ago

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 17, 2025, 8:05 AM EDT - 3 months ago

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Mar 6, 2025, 8:05 AM EST - 3 months ago

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 3, 2025, 4:15 PM EST - 3 months ago

Savara Announces Participation in the Leerink Global Healthcare Conference

Jan 30, 2025, 8:39 AM EST - 5 months ago

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Jan 29, 2025, 4:05 PM EST - 5 months ago

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Dec 18, 2024, 4:05 PM EST - 6 months ago

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Dec 17, 2024, 4:05 PM EST - 6 months ago

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 22, 2024, 8:05 AM EST - 7 months ago

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Nov 13, 2024, 8:05 AM EST - 7 months ago

Savara Announces Participation in Upcoming Healthcare Conferences

Nov 12, 2024, 8:05 AM EST - 7 months ago

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:05 PM EST - 8 months ago

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 22, 2024, 8:05 AM EDT - 8 months ago

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

Oct 1, 2024, 8:05 AM EDT - 9 months ago

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Sep 27, 2024, 8:05 AM EDT - 9 months ago

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Sep 24, 2024, 8:05 AM EDT - 9 months ago

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Sep 23, 2024, 8:05 AM EDT - 9 months ago

Savara to Host Analyst and Investor Webinar on September 30, 2024

Sep 8, 2024, 6:45 AM EDT - 10 months ago

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Sep 3, 2024, 4:05 PM EDT - 10 months ago

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:05 AM EDT - 11 months ago

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

Aug 12, 2024, 4:05 PM EDT - 11 months ago

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 28, 2024, 8:50 AM EDT - 1 year ago

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Jun 26, 2024, 9:36 AM EDT - 1 year ago

Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?

Jun 26, 2024, 6:41 AM EDT - 1 year ago

Savara's rare lung disease drug meets main goal in late-stage study

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Jun 25, 2024, 8:05 PM EDT - 1 year ago

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Jun 7, 2024, 5:56 AM EDT - 1 year ago

Savara: The Binary Bet On Phase 3 Data

May 29, 2024, 8:05 AM EDT - 1 year ago

Savara to Present at the Jefferies Global Healthcare Conference

May 19, 2024, 12:15 PM EDT - 1 year ago

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

TheThroatSlasher Jun. 12 at 1:07 PM

$SVRA this is a turd A slippery greasy stinky turd It was flushed 8-9 months ago but won’t go down, it just keeps floating

0 · Reply

arben1 Jun. 11 at 9:10 PM

$SVRA this company it’s all about survival. Lost money years go.just stay in my watch list to see at least patient can benefit

0 · Reply

art62 Jun. 4 at 10:18 PM

0 · Reply

GoldenTradesCapital Jun. 2 at 4:30 PM

1 · Reply

JambaPotato May. 30 at 2:05 PM

1 · Reply

art62 May. 30 at 3:41 AM

0 · Reply

Spacemonkey1 May. 29 at 9:30 PM

2 · Reply

Spacemonkey1 May. 29 at 9:16 PM

0 · Reply

Spacemonkey1 May. 29 at 9:15 PM

$SVRA I don’t know if there is a more damning statement about the utter leadership failure that occurred. Time to cut bait. Bring in someone experienced to get over the finish line

0 · Reply

Spacemonkey1 May. 29 at 9:13 PM

0 · Reply

RunnerSignals May. 29 at 8:32 PM

down big midday, but these comeback kings $SPTN $SVRA $TOI $HRL flipped the script and closed strong!

0 · Reply

JarvisFlow May. 29 at 11:30 AM

HC Wainwright & Co. has updated their rating for Savara ( $SVRA ) to Neutral with a price target of 2.

0 · Reply

RunnerSignals May. 29 at 3:33 AM

$SVRA watching for a pullback near $2.00. If it holds, could be setting up for a run toward $3+ risk defined, eyes open

0 · Reply

jdlman May. 29 at 1:36 AM

$SVRA lets rock

0 · Reply

anachartanalyst May. 28 at 8:02 PM

$SVRA https://anachart.com/wp-content/uploads/ana_temp/1748462516_soc-img.jpg

1 · Reply

JarvisFlow May. 28 at 4:06 PM

Evercore ISI Group updates rating for Savara ( $SVRA ) to In-Line, target set at 3 → 2.

0 · Reply

ScottyLikeyCoffee May. 28 at 2:58 PM

$SVRA The question was never about the drug. It works. Very little debate on that. It is all about execution. We will get there, but seemingly not before management trips on every pebble along the way.

0 · Reply

art62 May. 28 at 1:50 PM

$SVRA for the interested " After speaking to SVRA mgmt about Molbreevi's refuse-to-file (RTF) letter in aPAP rare lung disease (400M+ oppty), we remain 90%+ confident in an eventual FDA approval of the inhaled GM-CSF, based on the (+) Phase III data, a lack of approved aPAP therapies, and the fact that a redundant drug supplier (Fujifilm) comes online by the time of Q4:25 refiling. Also, we found 3 approved drugs that had resubmitted filings within 2-2.5 months of a CMC-related RTF."

0 · Reply

DARKP00L May. 28 at 1:08 PM

$SVRA 09:07 on May. 28 2025 Wells Fargo Maintains Overweight on Savara, Lowers Price Target to $7 #tradeideas

0 · Reply

GmKonig May. 27 at 8:48 PM

$SVRA whatever happened to the Breakthrough Designation and fast track to FDA approval, which included support from the FDA team?

1 · Reply

Longterm_Inv May. 27 at 7:32 PM

$RCKT $SVRA $PRTA $URGN Can't resist a bargain.

0 · Reply

Danboo May. 27 at 7:25 PM

$SVRA The first batch of management was incompetent on the science side. The second batch of management is incompetent on the submission side. As long as the science holds up the stock is probably worth holding. Even buying on the dip. The Board, however, needs to reevaluate the management, especially the CEO and the CMO if for no other reason to protect their own stock position. Medinfo

2 · Reply

Market Cap	356.04M
Revenue (ttm)	0.00
Net Income (ttm)	-95.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.20

Volume	1,618,100
Avg Vol	1,464,806
Day's Range	N/A - N/A
Shares Out	172.84M
Stochastic %K	9%
Beta	0.32
Analysts	Strong Sell
Price Target	$7.19